Table 1.
Design and Characterístics of Studies Included in the Meta-analysis
| Study | Design/NCT | Folow-up† | Age, yr † | Race - no.(%) | ECOG - no (%) | Histologic - no (%) | MMR status - no (%) | Previous therapy no (%) |
Treatment§ |
|---|---|---|---|---|---|---|---|---|---|
| MITO END-3, 2023 | RCT - Phase II/ NCT03503786 | 23·3 months (13.2–29.6) |
I: 66 C: 65 |
NA |
I: 0–49 (77.78) 1–14 (22.22) C:0–52 (83.87) 1–10 (16.13) |
I:Endometriod 44 (69.84) Serous − 10 (15.87) Others*-8 (12.7) C:Endometriod − 46 (74.19) Serous − 9 (14.52) Others*- 7 (11.29) |
I: dMMR − 26 (41.27) pMMR − 35 (55.56) C: dMMR − 31 (50) pMMR-19 (30.65) |
I: AC: 20 (32) AR: 28 (45): C: AC: 14 (22) AR: 29 (46) |
Avelumab 10 mg |
| NRG-GY018, 2023 | RCT - Phase III/ NCT03914612 |
12- dMMR 7.9 - pMMR |
I: 66 C: 65.1 |
I: White − 189 (77.14) Black − 28 (11.43) Other** − 27 (11.02) C: White − 191 (76.71) Black − 31 (12.45) Other** − 27 (10.84) |
I: 0–268(66.17) I − 127 (31.36) II − 10 (2.47) C: 0–271 (66.42) I − 123 (30.15) II − 14 (3.43) |
I:Endometriod − 246 (60.74) Serous − 82 (20.25) Others*- 77 (19.01) C:Endometriod − 238 (58.33) Serous − 73 (17.89) Others*- 97 (23.7) |
I: dMMR- 112 (27.65) pMMR − 293 (72.35) C: dMMR − 113 (27.70) pMMR- 295 (72.30) |
I: AC: 77 (19.01) AR: 155 (38.27) C: AC: 85 (20.83) AR: 174 (42.65) |
Pembrolizumab 200 mg |
| RUBY, 2023 | RCT - Phase III/ NCT03981796 | 24.8 ( 19.2 to 36.9) |
I: 64 C: 65 |
I: White − 304 (75.06) Black − 56 (13.83) Other** − 68 (16.79) C: White − 298 (73.04) Black − 60 (14.71) Other** − 65 (15.93) |
I:0–145(60.16) 1–96 (39.83) C: 0–160 (65.04) 1–86 (34.95) |
I:Endometriod − 134 (54.69) Serous 50 (20.41) Others*- 19 (7.76) C:Endometriod − 136 (54.62) Serous − 52 (20.88) Others*- 20 (8.02) |
I: dMMR: 53 (21.63) pMMR:192 (78.36) C: dMMR: 65 (26.10) pMMR: 184 (73.89) |
I: AR: 41 (16.73) C: AR: 41 (18.07) |
Dostarlimab 500 mg |
* Others: Dedifferentiates or unidifferentieates, Mixed epithelial, Pending, Adenocarcinoma, Clear cell; ** Others: American Indian or native, Unknown, Latin or hispanic, Caribeean, Asian, Multiracial; † Median range; § Day 1, IV; AC, Adjuvant chemotherapy; AR, Adjuvant radiotherapy; ECOG, Eastern Cooperative Oncology Group; dMMR, mismatch repair–deficient; MMR, Mismatch repair; NA, not available; pMMR, mismatch repair–proficient